Analyst Reaffirms Outperform Rating and 6 Price Target for Geron NASDAQ GERN
Wedbush analyst Robert Driscoll has once again expressed confidence in Geron (NASDAQ: GERN), reiterating an Outperform rating and a $6 ...
© 2024 Stocks Today
Tag: GERN
FDA Reservations on Geron Corporations Imetelstat Application for Anemia in LowerRisk MDS Patients
The FDA has expressed reservations regarding Geron Corporation's imetelstat application for anemia in lower-risk MDS patients, specifically questioning the balance ...
FDA Raises Concerns About Gerons Anemia Drug Imetelstat
Geron shares took a hit today as news broke that FDA staff reviewers have raised red flags about the potential ...
Analyst Reaffirms Buy Rating for Geron with 4 Price Target
Needham analyst Gil Blum has once again expressed optimism for Geron (NASDAQ: GERN), reiterating a Buy rating and holding steady ...
Upcoming FDA Advisory Committee Meeting for Imetelstat A Groundbreaking Treatment for Malignant Stem Cells
On January 30, 2024, the U.S. Food and Drug Administration (FDA) has announced an upcoming advisory committee meeting. The meeting ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Office Real Estate Investment Trusts REITs WellPositioned for ReturntoWork Trend